Table 1 Characteristics of participants reporting first and repeat infections (n = 23,591)
From: Prospective cohort study of fatigue before and after SARS-CoV-2 infection in the Netherlands
First infections1 (n = 22,705) | Repeat infections2 (n = 6414) | First or repeat infections during bivalent vaccination program3 (n = 7959) | |
|---|---|---|---|
Age at baseline4 | |||
18–59 years | 10970 (48.3%) | 3496 (54.5%) | 3438 (43.2%) |
60–85 years | 11735 (51.7%) | 2918 (45.5%) | 4521 (56.8%) |
Sex | |||
Female | 14652 (64.5%) | 4497 (70.1%) | 5261 (66.1%) |
Medical risk condition5 | |||
Yes | 6502 (28.6%) | 1660 (25.9%) | 2434 (30.6%) |
Variant of infection6 | |||
Delta | 1063 (4.7%) | - | - |
Omicron | 21642 (95.3%) | 6414 (100%) | 7959 (100%) |
BA.1/BA.2 | 11294 (49.7%) | 0 (0%) | 0 (0%) |
BA.4/BA.5 | 6119 (27.0%) | 294 (4.6%) | 2061 (25.9%) |
Post BA.5 | 4229 (18.6%) | 6120 (95.4%) | 5898 (74.1%) |
Vaccination status prior to the reported infection | |||
Unvaccinated | 437 (1.9%) | 72 (1.1%) | 69 (0.9%) |
Primary series | 1961 (8.6%) | 205 (3.2%) | 187 (2.3%) |
Booster | 20307 (89.4%) | 6137 (95.7%) | 7703 (96.8%) |
Acute symptoms | |||
Symptomatic | 21,337 (94.0%) | 5597 (87.3%) | 7229 (90.8%) |
Asymptomatic | 852 (3.8%) | 412 (6.4%) | 323 (4.1%) |
Missing | 516 (2.3%) | 405 (6.3%) | 407 (5.1%) |
